WEKO3
アイテム
Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia
http://hdl.handle.net/2298/12389
http://hdl.handle.net/2298/12389b19428ae-9d9f-4d67-a067-9fbeef6d09b1
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
IJH-KAWAGUCHI.pdf (447.5 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2009-09-18 | |||||
| タイトル | ||||||
| タイトル | Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題 | Chronic myeloid leukemia, Imatinib, Trough level, Body surface area | |||||
| 資源タイプ | ||||||
| 資源タイプ | journal article | |||||
| 著者 |
Kawaguchi, Tatsuya
× Kawaguchi, Tatsuya× 濱田, 哲暢× Hirayama, Chie× Nakashima, Reiko× Nambu, Takeru× Yamakawa, Yuji× Watanabe, Hiroshi× Horikawa, Kentaro× Mitsuya, Hiroaki× 齋藤, 秀之 |
|||||
| 内容記述 | ||||||
| 内容記述 | The standard dose of imatinib for the treatment of chronic-phase chronic myeloid leukemia (CML) is 400 mg/day. Some patients receive reduced doses of imatinib because of serious adverse effects. Recently, the effective plasma threshold for trough imatinib levels was demonstrated to be 1,002 ng/mL. In this study, we evaluated the association of an imatinib dose with trough plasma concentrations and clinical outcomes in 31 patients with chronic-phase CML who were treated at Kumamoto University Hospital. Twenty-seven patients were optimally treated with various doses of imatinib. The mean (±SD) trough plasma concentrations of imatinib were 1.40 ± 0.57 μg/mL in 13 patients receiving 400 mg/day and 1.15 ± 0.44 μg/mL in 9 patients receiving 300 mg/day as an effective dose. Mean trough levels of the two groups were not significantly different and exceeded the effective plasma threshold. Body surface area (BSA) was significantly smaller in patients receiving the reduced dose compared with those receiving the standard dose (p = 0.001). The effective imatinib dose was associated with age and gender as well as BSA. A reduced dose of 300 mg/day of imatinib may be sufficient for the treatment of CML patients with smaller body size, particularly when intolerability arises. Electronic supplementary material The online version of this article (doi:10.1007/s12185-009-0315-4) contains supplementary material, which is available to authorized users. |
|||||
| 書誌情報 |
International Journal of Hematology 巻 89, 号 5, p. 642-648, 発行年 2009-06-02 |
|||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 関連識別子 | https://doi.org/10.1007/s12185-009-0315-4 | |||||
| 情報源(ISSN) | ||||||
| 関連名称 | 0925-5710 | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| 形態 | ||||||
| 447480 bytes | ||||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| 日本十進分類法 | ||||||
| 主題Scheme | NDC | |||||
| 主題 | 493.17 | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 論文(Article) | |||||
| 資源タイプ・ローカル | ||||||
| 雑誌掲載論文 | ||||||
| 資源タイプ・NII | ||||||
| Journal Article | ||||||
| 資源タイプ・DCMI | ||||||
| text | ||||||
| 資源タイプ・ローカル表示コード | ||||||
| 01 | ||||||
